复旦大学:《药物设计学》课程教学资源(试卷习题)英文版习题集 Problems for Drug Design Courses(习题)

Problems for Drug Design Courses (D) 1. State the general factors that need to be considered when designing a drug? 2. Define the meaning of the terms pharmacokinetic phase and pharmacodynamic phase in the context of drug action. List the main general factors that affect these phases 3. Describe, in general terms, how the technique of deconvolution can be used to identify the most active component in a combinatorial library consisting of groups of mixtures of compounds 4. Outline the technique of high-throughput screening 5.(a) How do biochemical assays differ from whole cell assays. What are the advantages of whole cell assays over biochemical assays (b)What is the significance of hit rates when assaying the results of an assay? (c) Suggest reasons for abnormally low and high hit rates in a high-throughput screen for a specific type of activity 6. The drug amphetamine(PhCH2 CH(NH2)CH;) binds to the protein albumin in the blood stream Predict how a reduction in pH would be expected to influence this binding? Albumin is negatively charged at pH 7. 4 and electrically neutral at pH 5.0 7. Suggest strategies for improving the stability of compound a in the gastrointestinal tract. What could be the general effect of these strategies on the pharmaceutical action of compound A? (A) 8. Use the Lipinski rules to determine which of the following compounds are likely to be orally bioavailable. Give a reason for your decision. (Note: The logP values are imaginary but should be taken as a real for this question only!) COOH HOOC HOOC
Problems for Drug Design Courses (II) 1. State the general factors that need to be considered when designing a drug? 2. Define the meaning of the terms pharmacokinetic phase and pharmacodynamic phase in the context of drug action. List the main general factors that affect these phases. 3. Describe, in general terms, how the technique of deconvolution can be used to identify the most active component in a combinatorial library consisting of groups of mixtures of compounds. 4. Outline the technique of high-throughput screening 5. (a) How do biochemical assays differ from whole cell assays. What are the advantages of whole cell assays over biochemical assays. (b) What is the significance of hit rates when assaying the results of an assay? (c) Suggest reasons for abnormally low and high hit rates in a high-throughput screen for a specific type of activity 6. The drug amphetamine (PhCH2CH(NH2)CH3) binds to the protein albumin in the blood stream. Predict how a reduction in pH would be expected to influence this binding? Albumin is negatively charged at pH 7.4 and electrically neutral at pH 5.0. 7. Suggest strategies for improving the stability of compound A in the gastrointestinal tract. What could be the general effect of these strategies on the pharmaceutical action of compound A ? O HO HO O (A) 8. Use the Lipinski rules to determine which of the following compounds are likely to be orally bioavailable. Give a reason for your decision. (Note: The logP values are imaginary but should be taken as a real for this question only!) N H N OH COOH N N N O N N OH OH HO HOOC H2N CH3 NH2 N O OH HOOC H2N CH3 NH2 LogP=5.2 LogP=2.6 LogP=5.7

9. What is the significance structure of a drug as far as drug design is concerned? 10. Outline why the stereochemistry of a compound is important in drug design 11. Outline by means of suitable examples what the significance of (a) structurally rigid groups, (b) conformations and(c)configuration has on the design of new drugs 12. Why is water solubility an important factor in the action of drugs? 13. Define the meaning of the terms: (a)ideal solution and(b) polar solute 14. List the structural features that would indicate whether a compound is likely to be reasonably ater soluble Illustrate the answer by reference to suitable examples 15. Outline three general methods by which the water solubility of a compound could be improved without affecting its type of biological action 16. Suggest, by means of chemical equations, one route for the introduction of each of the following residues into the structure of 4-hydroxybenzenesulphonamide (a) an acid residue (b)a basic residue (c)a neutral polyhydroxy residue 17. State the full wording of the abbreviation"SAR" Describe the general way in which SAr is ed to develop a drug 18.(a) Explain why chloride and fluorine are normally the preferred halogen substituents for a SAR Investigation (b) What alternative halogen containing group could be used in place of chlorine? Give one reason for the use of this group 19. Explain the meaning of the terms:(a) bioisostere and(b) pharmacophore 20. Suggest how the introduction of each of the following groups into the structure of a lead could be expected to affect the pharmacokinetics of the resultant analogue:(a) a sulphonic acid group, (b) a methyl group and (c)a thiol group. Assume that these groups are introduced into the section of the lead, structure that does not contain its pharmacophore
9. What is the significance structure of a drug as far as drug design is concerned? 10. Outline why the stereochemistry of a compound is important in drug design. 11. Outline by means of suitable examples what the significance of (a) structurally rigid groups, (b) conformations and (c) configuration has on the design of new drugs. 12. Why is water solubility an important factor in the action of drugs? 13. Define the meaning of the terms: (a) ideal solution and (b) polar solute 14. List the structural features that would indicate whether a compound is likely to be reasonably water soluble. Illustrate the answer by reference to suitable examples. 15. Outline three general methods by which the water solubility of a compound could be improved without affecting its type of biological action. 16. Suggest, by means of chemical equations, one route for the introduction of each of the following residues into the structure of 4-hydroxybenzenesulphonamide. (a) an acid residue (b) a basic residue (c) a neutral polyhydroxy residue. 17. State the full wording of the abbreviation “SAR”. Describe the general way in which SAR is used to develop a drug. 18. (a) Explain why chloride and fluorine are normally the preferred halogen substituents for a SAR investigation. (b) What alternative halogen containing group could be used in place of chlorine? Give one reason for the use of this group. 19. Explain the meaning of the terms: (a) bioisostere and (b) pharmacophore. 20. Suggest how the introduction of each of the following groups into the structure of a lead could be expected to affect the pharmacokinetics of the resultant analogue: (a) a sulphonic acid group, (b) a methyl group and (c) a thiol group. Assume that these groups are introduced into the section of the lead, structure that does not contain its pharmacophore

21. Outline the fundamental principle underlying the Qsar approache to drug design 22. Lipophilicity, shape and electron distribution all have major influence on drug activity. State the parameters that are common used as a measure of these properties in the QSar approach to drug design. 23. What are the advantages and disadvantages of using molecular mechanics to model molecular structures 24. Explain the significance of the terms global and local minimum energy conformations 25 Describe, in outline only, what is meant by(a) molecular dynamics and(b) docking 26)(a)What is the principle that forms the basis of the quantum mechanical approach to molecular modeling? (b) State and name the equation that is the starting point of the wave mechanical approach to molecular modeling 27 Explain the meaning of the term pharmacophore 28. Explain why a molecular with a flexible structure would be more likely to be more active than its analogue with a rigid structure. The compound a and b both bind to the same target site, which of them would you expect to be the most active? State the basis of your decision NH2 H3C NH2
21. Outline the fundamental principle underlying the QSAR approache to drug design. 22. Lipophilicity, shape and electron distribution all have major influence on drug activity. State the parameters that are common used as a measure of these properties in the QSAR approach to drug design. 23. What are the advantages and disadvantages of using molecular mechanics to model molecular structures. 24. Explain the significance of the terms global and local minimum energy conformations. 25. Describe, in outline only, what is meant by (a) molecular dynamics and (b) docking 26) (a) What is the principle that forms the basis of the quantum mechanical approach to molecular modeling? (b) State and name the equation that is the starting point of the wave mechanical approach to molecular modeling. 27 Explain the meaning of the term pharmacophore. 28. Explain why a molecular with a flexible structure would be more likely to be more active than its analogue with a rigid structure. The compound A and B both bind to the same target site, which of them would you expect to be the most active? State the basis of your decision. H3C NH2 H3C NH2 (A) (B)
按次数下载不扣除下载券;
注册用户24小时内重复下载只扣除一次;
顺序:VIP每日次数-->可用次数-->下载券;
- 复旦大学:《药物设计学》课程教学资源(试卷习题)习题集(答案).doc
- 复旦大学:《药物设计学》课程教学资源(试卷习题)习题集(习题).doc
- 复旦大学:《药物设计学》课程教学资源(案例分析).pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-V SYNTHESIS, LIPOPHILICITY DETERMINATION, AND QSAR STUDY OF CHALCONES AND ANALOGS WITH ANTITUMORAL ACTIVITY.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-IV TOXICITY SCREENING OF THERAPEUTIC DRUGS.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-III-4E MEDICINAL CHEMISTRY AND MOLECULAR MODELING:AN INTEGRATION FOR THE TEACHING OF DRUG STRUCTURE–ACTIVITY RELATIONSHIP AND THE MOLECULAR BASIS OF DRUG ACTION.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-III-2E A LABORATORY COURSE IN MEDICINAL CHEMISTRY INTRODUCING MOLECULAR MODELING.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-III-1E STRUCTURAL DATA:THE BASIS FOR MOLECULAR MODELING.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-II COMPARING LOG P CALCULATIONS BY THE GHOSE–CRIPPEN AND VILLAR METHODS.pdf
- 复旦大学:《药物设计学》课程教学资源(虚拟实验室课外实践)Exercises for Drug Design Courses_Practice-I HYDROPHOBICITY IN DRUG DESIGN.pdf
- 《药物设计学》课程教学资源(参考教材)国外药学专著译丛《有机药物化学》电子书(原著第二版,共八章,[美]R.B.西尔弗曼 Richard B. Silverman,主译:郭宗儒).pdf
- 《药物设计学》课程教学资源(参考教材)药物设计与药物行为的有机化学(第二版)The Organic Chemistry of Drug Design and Drug Action.pdf
- 《药物设计学》课程教学资源(参考教材)药物化学精览(中文本,著:[英]G.帕特里克,译:孙铁民、郭春).pdf
- 《药物设计学》课程教学资源(参考教材)医药化学(影印版)Medicinal Chemistry.pdf
- 《药物设计学》课程教学资源(参考教材)计算机辅助药物设计导论(编著:叶德泳)An Introduction to Computer-Aided Drug Design.pdf
- 复旦大学:《药理学》精品课程教学资源(习题)作业自测习题(含答案).docx
- 《护理药理学》课程教学资源(PPT课件讲稿)课程介绍.ppt
- 黑龙江八一家垦大学:动物药学专业就业分析(姚启程).pptx
- 武汉大学药学院博士课程:现代药学研究新进展(主讲:台万一).pdf
- 《药理学》课程教学资源(PPT课件讲稿)第二章 药物代谢动力学.ppt
- 复旦大学:《药物设计学》课程教学资源(试卷习题)英文版习题集 Problems for Drug Design Courses(答案).doc
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶点认定_The domain responsible for sphingomyelin synthase(SMS)activity.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶点认定_人巨细胞病毒耐药相关蛋白PUL97局部结构模拟和突变分析.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶点认定_Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶点认定_Evaluation of various inverse docking schemes in multiple targets identification.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶向药物设计_Choline-Derivate-Modifi ed Nanoparticles for Brain-Targeting Gene Delivery.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶向药物设计_Design, synthesis, and bioavailability evaluation of coumarin-based prodrug of meptazinol.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)靶向药物设计_Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)基于靶点结构的药物设计_新型苯并硫氮杂卓酮类非ATP 竞争GSK-3β抑制剂的设计、合成和活性评价.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)基于靶点结构的药物设计_Molecular Modeling of the Three-Dimensional Structure of Human Sphingomyelin Synthase.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)基于靶点结构的药物设计_Modeling the Interaction between Glycogen Synthase Kinase 3β(GSK-3β)and Its Non-ATP Competitive Inhibitors.pdf
- Investigation of the binding mode of (−)-meptazinol and bis-meptazinol derivatives on acetylcholinesterase using a molecular docking method.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)基于靶点结构的药物设计_Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice.pdf
- Bis-(-)-nor-meptazinols as Novel Nanomolar Cholinesterase Inhibitors with High Inhibitory Potency on Amyloid-beta Aggregation.pdf
- The Crystal Structure of a Complex of Acetylcholinesterase with a Bis-(-)- nor-meptazinol Derivative Reveals Disruption of the Catalytic Triad.pdf
- Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3b (GSK-3b).pdf
- Molecular Modeling of the 3D Structure of 5‑HT1AR_Discovery of Novel 5‑HT1AR Agonists via Dynamic Pharmacophore-Based Virtual Screening.pdf
- 复旦大学:《药物设计学》课程教学资源(教学研究)基于靶点结构的药物设计_Micelle-Based Brain-Targeted Drug Delivery Enabled by a Nicotine Acetylcholine Receptor Ligand.pdf
- Molecular Insights into the D1R Agonist and D2R-D3R Antagonist Effects of the Natural Product (−)-Stepholidine_Molecular Modeling and Dynamics Simulations.pdf
- Bis(9)-(−)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice.pdf